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Transdermal drug delivery has been accepted as a potential non-invasive route of drug
administration, with advantages of prolonged therapeutic action, decreased side effect,
easy use and better patient compliance. However, development of transdermal products is
primarily hindered by the low permeability of the skin. To overcome this barrier effect,
numerous new chemicals have been synthesized as potential permeation enhancers for
transdermal drug delivery. In this review, we presented an overview of the investigations
in this field, and further implications on selection or design of suitable permeation en-
hancers for transdermal drug delivery were also discussed.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
For decades, utilization of skin as a route for delivering drugs
has been an attracting alternative to conventional methods
including injections and tablets. Its advantages include the
avoidance of pain, elimination of hepatic first-pass meta-
bolism, sustained drug release for a prolonged period, easy
use andwithdrawal in case of side effects. However, themajor
limitation for transdermal drug delivery system (TDDS) is also
the skin itself. As the outmost layer of the epidermis, the330.
L. Fang).
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sevier
ang Pharmaceutical Univstratum corneum (SC) provides an outstanding barrier to-
wards the absorption of chemical and biological toxins [1]. It
has a unique hierarchical structure, which is filled with mul-
tiple lipid bilayers and the embedded corneocytes [2,3]. In
theory, there are twomain permeation routes through the SC,
first the intracellular route across the corneocytes as well as
the lipid matrix, and second the intercellular route via the
lipid domains between the corneocytes. The lipid phase is
continuous throughout the SC, and therefore the penetrating
substances must interact with this phase whether they
penetrate transcelluarly or intercelluarly.sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
Table 1 e Ceramide analogs with different polar heads.a
Polar head Structure No. R1 R2 ER (IPM) ER (W) Ref.
Amino acid 1 H C11H23 1.11 12.50 15
2 CH2OH C11H23 1.21 2.74
3 H (CH2)7CH]CH(CH2)7CH3 1.49 1.26
Dipeptide 4 H H 1.09 2.28 15
5 CH2OH CH2OH 1.07 1.26
L-serine þmaleic acid 6 CH2OH e 1.45 1.36 15
a The enhancing activity of these compounds was studied in vitro, using water (W) and isopropyl myristate (IPM) as the donor vehicle, human
cadaver skin as the transdermal barrier and theophylline as the model drug.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 5 1e6 452In order to facilitate thepassage ofmolecules through theSC,
transdermal permeation enhancers have been extensively
studied. Up to date, more than 360 chemicals have been
demonstrated to enhance the skin permeability [4], including
terpenes, sulphoxides, laurocapram,pyrrolidones, fattyacidand
fatty alcohol, alcohol and glycol, surfactants, urea, and so on.
However, as a result of their incompatibility in the formulation
or local irritation issues, few to date have been routinely incor-
porated in the currently marketed transdermal products [5].
Therefore, exploration of chemicals to safely improve the skin
permeability remainsan intensiveareaof transdermal research.
There have been several reviews discussing the enhance-
ment activity of the classic permeation enhancers that are
commonly used in the transdermal products [5e8]. However,
a detailed introduction of those potential candidates newly
developed is still lacking. Therefore, this paper provides a
review on the current researches in this field, which might be
helpful the selection or development of a suitable absorption
promoter in TDDS.2. Novel permeation enhancers
2.1. Ceramide analogs
The lipids in the SC consist of ceramides, cholesterol and fatty
acids, as well as a small quantity of cholesterol sulfate [9,10]. It
has been known that ceramides are the main components
responsible for the barrier effect of the SC. Structurally, they
are amphiphilic molecules, containing two long hydrocarbon
tails and an acylamide polar head [11,12]. Va´vrova´ et al.
believed that certain structure similarity might exist betweenenhancers and ceramides, so that the enhancer molecules
could insert themselves between the hydrophobic tails of the
ceramide bilayers and weaken the continuity of the lipid
barrier [13]. In their study, a series of ceramide analogs (Table
1) with two kinds of polar heads based on L-serine and glycine
were respectively synthesized, and the relationship between
the properties of the polar heads and enhancement activity
was discussed. The result indicated that although these
compounds were inactive in isopropyl myristate (IPM), sig-
nificant enhancement effects were observed when they were
used in the water (W) suspensions. Especially, compound 1
with the simplest glycine group as the polar head structure
was the most potent one, and its promoting activity was
significantly higher than compound 2, an L-serine based de-
rivative which had a hydroxyl group in the polar head.
Furthermore, these two compounds were both more active
than their respective analogs with dipeptide as the polar
heads, whichwere shown by compound 4 and 5. These results
led to a hypothesis that the increasing size and H-bonding
ability would decrease the activity of the ceramide analogs,
and it might account for the little enhancing activity of com-
pound 6, which possessed a large polar head with three hy-
droxyl groups. In addition, the study also suggested that the
introduction of a double bond into the hydrocarbon chain did
not contribute much to the activity of the present ceramide
analog, which was demonstrated by the compound 3.
To further examine the aforementioned hypothesis,
ceramide analogs (Table 2) with six different chain lengths
(compound 7e12) and eight different polar head groups
(compound 7, 13, 15e20) were synthesized [14]. When
analogs of the same chain length were compared, the best
enhancement effect was observed with compound 7 and
Table 2 e Ceramide analogs with different polar head and hydrophobic chain length.a
Polar head Structure No. R1 R2 R3 R4 ER (W) Ref.
Amino acid 7 C12H25 C11H23 H e 4.53 16
8 C11H23 C10H21 H 2.26
9 C10H21 C9H19 H 3.19
10 C9H19 C8H17 H 2.16
11 C8H17 C7H15 H 2.35
12 C12H25 (CH2)7CH]CH(CH2)7CH3 H 0.45
13 C12H25 C11H23 CH2OH 1.24
14 C12H25 (CH2)7CH]CH(CH2)7CH3 CH2OH 0.45
Dipeptide 15 C12H25 C11H23 H H 1.00 16
16 C12H25 C11H23 H CH2OH 0.94
17 C12H25 C11H23 CH2OH CH2OH 0.94
Amino acid þmaleic acid 18 C12H25 C12H25 H e 6.64 16
Amino acid þ tartaric acid 19 C12H25 C12H25 H e 1.04 16
20 C12H25 C12H25 CH2OH e 0.83
a The enhancing activity of these compounds was studied in vitro, using water (W) as the donor vehicle, porcine ear skin as the transdermal
barrier and theophylline as the model drug.
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polar head with the smallest size and that with the lowest H-
bonding ability, which further confirmed the previous hy-
pothesis that decreasing the size or H-bonding ability of the
polar heads of ceramide analogs would contribute to their
transdermal enhancement activity. Considering the fact that
the polar head of compound 18 is relatively large, comparable
to that of compound 15e17 which were inactive as perme-
ation enhancers, it was concluded that H-bonding might be
more significant than the polar head size or other factors. In
addition, the optimum chain length of the ceramide analogs
was found to be 12 carbons (compound 7), whichmight be due
to its favorable interaction with the intercellular skin lipids.
2.2. Azone analogs
Azone (1-dodecylazacycloheptan-2-one or laurocapram, com-
pound 21, Table 3) is the first molecule specially designed as a
skin permeation enhancer [10]. It has been demonstrated to
enhance the transdermal absorption of a wide variety of drugs
[15]. Azone probably exerts its permeation enhancing effects
mainly via the interactionwith the lipid domains of the SC. The
‘soup spoon’ structure would make it more likely to partition
into the bilayer lipids, where Azone might exist dispersed or in
separated domains to disrupt the organized lipid packing [5].Although FDA has not approved for its use in pharmaceutical
products for its slight side effects, Azone is recorded in the
Chinese Pharmacopoeia and widely used in China. To improve
its properties, hundreds of Azone like compounds have been
synthesized, which provide a huge amount of information
about the molecular design for Azone analogs [16].
The structure of Azone can be divided into two parts, viz.
the hydrophobic chain and the polar cycle head (the hetero-
cycle and a carbon on the hydrophobic chain). Change of the
chain length was the common structural modification to the
hydrophobic tails. By contrast, the modifications of the polar
head group was complex, and usually carried out by alterna-
tion of heterocyclic ring size, isosteric replacements of N, O,
and C atoms, removal of function groups, addition of other
polar groups onto the a carbon of the hydrophobic chain [16].
Since the data was too large to easily pick out the information
of interest, only key structural requirement for Azone like
compounds were summarized here. To avoid the inter-
laboratory differences such as sample types and solvent sys-
tems for the enhancers, activity of Azone analogs were
compared using the data from one research group.
2.2.1. The optimal hydrocarbon chain length
The enhancement activities of enhancers always increased as
the length of the hydrophobic chains increased, and when the
Table 3 e The optimal chain lengths for Azone analogs
with different polar heads.
Polar head No. The optimal chain length Ref.
21a C12H25 17
22b C10H21 18
23c C10H21 19
24c C14H29 19
25d C11H23, C12H25 20
26e C8H17 21
a Human stratum corneum in vitro, pretreated with enhancers in
the solution of propylene glycol, desglycinamide arginine vaso-
pressin as a model drug [17].
b Rabbit skin in vivo, treated with petrolatum ointments containing
salicylic acid [18].
c Hairless mouse skin in vitro, treated with enhancer solution of
propylene glycol containing hydrocortisone 21-acetate as a model
drug [19].
d Hairless mouse skin in vitro, treated with solution of propylene
glycol saturated with benazepril and hydrocortisone as model
drugs, as well as 5% (w/v) enhancers [20].
e Hairless mouse skin in vitro, treated with an enhancer/PBS solu-
tion containing b-estradiol, corticosterone and hydrocortisone as
model drugs [21].
Table 4 e Azone analogs with different polar cycle size
and heteroatoms on the polar head.a
No. Structure ER
Azone 22.1
27 22.2
28 27.6
29 7.9
30 6.7
31 21.0
32 15.1
a The enhancing experiments were performed in vitro, using hair-
less mouse skin as the transdermal barrier, which was first pre-
treated with these compounds in the solution of propylene glycol
(PG), and then treated with the suspension of hydrocortisone.
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tivities rather decreased [17]. This kind of parabolic depen-
dence was frequently observed in the study of structure-
activity relationship for amphiphilic permeation enhancer.
The optimal hydrocarbon chain length for Azone analogs
were always observed between 8 and 14 carbons, whichwould
vary according to their different polar heads (Table 3). The
action of an enhancer was considered to be dependent on the
balance between its hydrophilic and lipophilic nature, and
therefore different length of alkyl chain was required for best
incorporation of the enhancer with different polar heads into
the skin lipid bilayers. This effect would produce a free space
within the lipid lamellae, and thereby producing lateralfluidization of the tightly packed lamellar lipids. In addition,
these compounds could also form separate phases within the
lipid lamellae, providing a more permeable shortcut for
penetrating compounds.
2.2.2. Heterocyclic ring size
Michniak et al. compared the transdermal promoting activity
of Azone and its analogs containing five or six member cycle.
As shown in Table 4, the presence of five-member cycle
(compound 28) increased the activity, while six (compound 27)
and seven member cycle (Azone) analogs exhibited lower ac-
tivity [22]. TheH-bonding net formedbetween the head groups
is accepted as an important factor in stabilizing the lipid bi-
layers [23]. Azone analogs with a small polar head might be
expected to be situated well into the polar lipid domain, thus
disrupting the ordered organization of the lipid layers.
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The effect of the heteroatom in the polar head of Azone ana-
logs was investigated in the study [22]. As shown in Table 4,
removal of the nitrogen atom in the polar heads of compound
27 and 28 resulted in a significantly decrease in the promoting
activity, which were demonstrated by compound 29 and 30.
By contrast, in the polar cycle heads of compound 27 and 28,
introduction of another heteroatom generated compounds
with better promoting properties, i.e. compound 31 and 32.
These findings demonstrated that the heteroatom in the polar
head was essential for the activity of Azone analogs.
2.2.4. The carbonyl in polar head
Hadgraft et al. evaluated the modifying effects of Azone and
its several analogs on the transdermal absorption of metro-
nidazole (Table 5) [23]. Moving the carbonyl group of Azone
from the cycle head to its a carbon of the alkyl chain gave the
product of compound 32, which showed a comparable
enhancement effect in comparison of Azone. However, isos-
teric substitution of carbonyl oxygen in Azone by sulfur led to
a dramatically decreasing activity, which was demonstrated
by compound 33. Additionally, when the carbonyl group of
Azone was reduced into the alkyl, its enhancing activity also
significantly decreased, as shown by compound 34 [24].
Therefore, it appeared that the carbonyl in polar head was
needed for activity.2.3. Menthol derivatives
Since its introduction, terpenes have attracted much interest
as potential transdermal permeation enhancers [25,26]. OfTable 5 e Alternation of the carbonyl group in the polar
head of Azone analogs.
No. Structure ER
Azone 6.7a/19.51b
32 6.4a
33 1.4a
34 15.33b
a Human skin in vitro, treated with ethanolic solution containing
1% enhancer and 5 mmol/ml metronidazole as a model drug.
b Hairless mouse skin in vitro, treated with propylene glycol con-
taining enhancers and hydrocortisone 21-acetate as a model drug.these compounds, menthol (compound 35, Table 6) repre-
sents a traditional, and arguably, the most common one that
has been known as a lipid disordered agent to disrupt the
molecular organization of the bilayer lipids in SC [9,27e29]. In
spite of its enhancement activity and relatively low skin irri-
tation, application of menthol is often hindered by its unde-
sirable odor and high volatility. Therefore,many derivatives of
menthol have been synthesized in the identification of
promising candidates with suitable properties for application
in TDDS.
2.3.1. Etherified derivatives
Obata et al. first found that an ether derivative of menthol, O-
ethylmenthol (compound 36, Table 6), had an excellent ac-
tivity toward the in vivo percutaneous absorption of ketopro-
fen alcoholic hydrogels through the rabbit skin [30e33]. Based
on this finding, a series ofmono- and disubstituted derivatives
of cyclohexane with an O-ethyl group were synthesized and
evaluated for their absorption enhancement activity [34]. As
shown in Table 6, in the list of mono-substituted derivatives
(compound 37e54), most of them acted better than O-ethyl-
menthol, except for methyl-substituted products (compound
37, 43, 49). Among the C-2 substituted compounds (compound
37e42), compound 40 which has an isopropyl group showed
the highest activity. Among the C-3 substituted compounds
(compound 43e48), isopropylated or butylated derivatives
(compounds 46 and 47) showed the highest activity. Among
the C-4 substituted compounds (compounds 49-54), com-
pound 52 which also has an isopropyl group showed the
highest activity. In the list of the di-substituted derivatives
(compound 55e70), all of them had a similar or better effect
thanMET. The study also suggested that the irritation potency
of these derivatives correlated well with their enhancing ac-
tivity, and both of them were parabolically dependent with
the log P of the compounds. As an exception, 1-O-ethyl-3-
butylcyclohexanol (OEBC, compound 47) was proved to be a
safe and prominent candidate that promoted the transdermal
absorption of ten different model drugs, yet exhibiting rather
low irritation [35]. In addition, thiomenthol derivatives (com-
pound 71-83, Table 7) were also synthesized formore effective
and safer permeation enhancer candidates. However, severe
skin irritation was produced by these compounds, although
some of them had strong promoting activity [36].
2.3.2. Esterified derivatives
Zhao et al. employed menthol as a lead compound and syn-
thesized O-acylmenthol derivatives (Table 8) with a series of
saturated fatty acid (C2eC18) and pharmaceutical excipient
acids [37,38]. Indomethacin, ketoprofen, lidocaine, isosorbide
dinitrate and 5-fluorouracil were selected as model drugs
based on their different physicochemical properties. In the
case of saturated fatty acid esters, most of them exhibit good
enhancing effect on the transdermal absorption of indo-
methacin, ketoprofen and isosorbide dinitrate, among which
compound 88 and 89 respectively produced the greatest
enhancing activity towards indomethacin and isosorbide
dinitrate. For ketoprofen, compounds with shorter acyl-
chains, such as compound 85 and 86 generally provided the
best enhancing effect. However, most of these compounds
had no enhancing activity towards 5-fluorouracil and
Table 6 e Structural modification on O-ethylmenthol.a
Structure No. R Structure No. R
35 e 49 CH3
50 CH2CH3
51 CH2CH2CH3
52 CH(CH3)2
53 CH2(CH2)2CH3
54 CH2(CH2)3CH3
36 e 55 2,2-di CH3
56 3,3-di CH3
57 4,4-di CH3
37 CH3 58 2,3-di CH3
38 CH2CH3 59 2,4-di CH3
39 CH2CH2CH3 60 2,5-di CH3
40 CH(CH3)2 61 2,6-di CH3
41 CH2(CH2)2CH 62 3,4-di CH3
42 CH2(CH2)3CH 63 3,5-di CH3
64 2-CH3, 4-CH2CH3
43 CH3 65 3-CH3, 4-CH2CH3
44 CH2CH3 66 5-CH3, 2-CH2CH3
45 CH2CH2CH3 67 2-CH3, 4-CH(CH3)2
46 CH(CH3)2 68 2-CH3, 5-CH(CH3)2
47 CH2(CH2)2CH 69 3-CH3, 4-CH(CH3)2
48 CH2(CH2)3CH 70 3-CH3, 5-CH(CH3)2
a The enhancing activity of these compounds was studied in vivo using rat skin as the transdermal barrier, and ketoprofen hydrogels as the
model drug.
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pharmaceutical excipient acids (lactic acid, cinnamic acid,
salicylic acid and oleic acid), all of the compounds except for
compound 99 promoted the transdermal absorption of iso-
sorbide dinitrate very well. Compound 98 and 100 exhibited
good promoting effect for ketoprofen. However, for 5-fluoro-
uracil and lidocaine, only compound 97 exhibited good ac-
tivity, and for indomethacin, only compound 100 had
enhancing effectiveness. The in vivo results obtained from theTable 7 e Thiomenthol derivatives.a
Structure No.
71 R1: H
72 R1: H R1: CH3
73 R1: H
74 R1: H
75 R1: H
76 R1: CH3
77 R1: CH3
78 R1: H
79 R1: CH3
80 R1: CH3
81 R1: H
82 R1: CH3
83 R1: H
a The enhancing activity of these compounds was studied in vivo using
model drug.patches containing these compounds as permeation en-
hancers were in good agreement with the plasma concentra-
tion predicted form the in vitro data [39]. The study also
revealed that the drug lipophilicity had a significant impact on
the promoting activity of the O-acylmenthol derivatives, and a
parabolic relationship between flux and log Ko/w of the drugs
was observed. In recent investigations, the O-acylmenthol
derivatives were demonstrated their enhancing activity to-
wards several drugs with different physiochemical properties,R
R2: CH3R2: CH2CH3R2: CH2CH3 R3: H
R2: CH2CH3 R3: H
R2: CH2CH3 R3: CH(CH)3
R2: CH2CH3 R3: CH2CH2CH2CH3
R2: CH3 R3: CH(CH)3
R2: H R3: CH2CH2CH3
R2: CH2CH3 R3: CH(CH)3
R2: CH2CH3 R3: CH(CH)3
R2: CH2CH3 R3: CH3
R2: CH2CH3 R3: CH2CH3
R2: CH2CH3 R3: H
R2: CH3R2: CH2CH3R2: CH2CH3 R3: CH2CH3
R2: CH2CH3 R3: CH3
rat skin as the transdermal barrier and ketoprofen hydrogels as the
Table 8 e Ester derivatives based on l-menthol.a
Structure No. R ERa
LD IM 5-FU ISDN KP
Menthol e 0.84 0.78 0.51 1.10 1.09
84 CH3 0.96 1.97 0.35 0.50 1.30
85 CH2CH3 1.21 2.01 0.40 1.38 1.87
86 (CH2)2CH3 1.20 0.05 0.23 0.95 1.81
87 (CH2)3CH3 0.90 1.21 0.44 1.12 1.43
88 (CH2)4CH3 1.00 0.77 0.71 1.91 1.82
89 (CH2)5CH3 1.58 3.70 0.63 1.47 1.59
90 (CH2)6CH3 1.18 0.53 0.11 1.51 1.79
91 (CH2)7CH3 1.03 2.09 0.98 1.27 1.69
92 (CH2)8CH3 0.95 1.78 0.53 1.73 1.25
93 (CH2)10CH3 1.26 1.13 0.52 1.09 1.32
94 (CH2)12CH3 0.72 0.78 1.34 1.22 1.39
95 (CH2)14CH3 0.71 0.78 1.11 1.43 1.35
96 (CH2)16CH3 0.73 0.75 0.20 1.00 1.44
97 3.17 0.04 3.74 1.49 0.44
98 0.84 1.13 0.71 1.29 1.94
99 1.08 0.85 0.13 1.07 1.27
100 0.92 1.66 0.81 1.67 1.84
a The enhancing activity was studied in vitro using IPM as the donor vehicle and rat skin as the transdermal barrier.
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for the enhancer action is still being studied.
2.4. Transkarbams
Esters of amino acids were often synthesized as biodegradable
permeation enhancers because of their safe and well-known
metabolites. Dolezal et al. first found that an acyclic Azone
analog, i.e. dodecyl-6-aminohexanoate (DDEAC, Fig. 1A), had a
markedly higher activity and a lower toxicity than Azone [42].
However, it was indicated that the behavior of the enhancer
did not correspond to that of an amino ester molecule. DDEAC
would react with the carbon dioxide by the free amino group
and form another two-chain enhancer with a carbamate saltforming its polar head, termed as Transkarbam 12 (T12),
which was suggested to be responsible for the enhancing ef-
fect [43]. T12 has been demonstrated to be an effective and
biodegradable skin permeation enhancer. In addition, lots of
efforts have been made to explore its structure-activity rela-
tionship by structuralmodification at its threemolecular sites,
which was illustrated in Fig. 1B.
2.4.1. Carbamate salt
The authors believed that the carbamate salt (Part I) in the
polar head of T12 played an essential role in its transdermal
enhancement activity. To examine this hypothesis, a series of
T12 derivatives with different polar heads (Table 9) were
synthesized and studied, including the analogs with carbonic
Fig. 1 e Chemical structures of DDEAC (A) and T12 (B).
Structural modifications of T12 were carried out mainly at
three molecular sites as indicated in its chemical structure.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 5 1e6 458and carbamic acid esters in the polar heads, which were
shown by compound 101e114 [44]. The results showed that
although in aqueous suspension some of them were slightly
more effective than T12; however, none of them could be
comparable to T12 neither in PG/W nor IPM systems. There-
fore, it was clear that the transdermal enhancing ability of T12
was closely related to the carbamate group, i.e. carbamic acidTable 9 e T12 analogs based on carbonic and carbamic acid es
Structure NO. n R1 R2
T12 101 e e e
102 4 H C10H
103 4 H C10H
104 2 CH3 C12H
105 2 CH3 C12H
106 4 H C12H
107 4 H C12H
108 3 e e
109 3 e e
110 4 e e
111 e e e
112 e e e
113 3 e e
114 4 e e
a The enhancing activity of these compounds was studied in vitro, using
model drug. Water (W), isopropyl myristate (IPM) and propylene glycol/wsalt. A further study revealed that the possible mechanisms
for T12 action could be that CO2 was released from the polar
moiety under the mildly acidic condition of the skin, causing
the disruption of the highly ordered lipid lamellae. Addition-
ally, its degradation product, protonated dodecyl-6-
aminohexanoate (DDEAC) was also an active enhancer [45].
2.4.2. Ester linkage
The modifications of ester bonds (Part II) in the molecule of
T12 were also taken into consideration and the corresponding
carbonate (compound 115e120), carbamate (compound
121e130), ketone (compound 131e132), amide (compound
133e140), alkane (compound 141) analogs were synthesized,
which were shown in Table 10 [46,47]. In IPM suspension,
analogs of amides (compound 133e140) and compound 119
were comparable to that of T12. However, in PG/W vehicle, the
activity of T12 was much better than all the synthesized
compounds. The best chain length was further investigated
among the amide analogs. As expected, a parabolic relation-
ship was obtained with maximum at nonyl derivative (com-
pound 137) in both vehicles and branching of the hydrocarbon
chain decreased the activity dramatically. Based on these
observations, it was found that ester bonds in T12 were
indispensible for its enhancement effect.ters.a
R3 X ERa
W PG/W (6:4) IPM
e e 1.90 22.80 6.56
21 C2H5 NH 3.37 1.36 1.75
21 C12H25 NH 1.13 2.66 1.48
25 C2H5 NH 1.48 1.45 1.77
25 C12H25 NH 1.70 1.11 1.15
25 C2H5 O 2.40 2.13 1.07
25 C12H25 O 2.49 1.13 1.29
e NH 0.91 3.29 1.23
e O 1.76 3.70 1.39
e O 0.80 1.24 1.49
C2H5 e 1.83 1.52 1.01
C12H25 e 0.77 0.47 0.57
e e 2.27 2.63 1.29
e e 1.12 1.02 1.07
porcine ear skin as the transdermal barrier, and theophylline as the
ater (PG/W) was respectively used as the different donor vehicles.
Table 10 e Ketone, amide, and alkane analogs of T12.a
Structure NO. n R ERa
W PG/W (6:4) IPM
T12 e e 1.90 22.80 6.56
115 5 C8H17 4.1 12.4 2.2
116 5 C10H21 5.1 11.8 5.5
117 5 C12H25 2.5 7.4 2.9
118 6 C8H17 4.6 7.1 3.4
119 6 C10H21 4.7 7.9 9.7
120 6 C12H25 1.6 8.4 4.0
121 4 C8H17 1.6 3.2 4.8
122 4 C9H19 1.9 6.3 5.6
123 4 C10H21 2.1 5.6 3.6
124 4 C11H23 1.5 2.9 2.5
125 5 C10H21 1.5 5.3 2.6
126 5 C11H23 1.0 2.3 2.2
127 5 C12H25 1.2 1.7 1.7
128 6 C10H21 1.2 4.3 3.1
129 6 C11H23 1.5 3.7 1.7
130 6 C12H25 1.3 1.9 0.8
131 5 C11H23 e 3.8 2.6
132 5 C12H25 3.4 1.1
133 5 C6H13 e 3.8 4.9
134 5 C7H15 e 3.8 6.8
135 5 Octane-2-yl e 2.2 5.2
136 5 C8H17 e 5.0 7.0
137 5 C9H19 e 8.6 8.6
138 5 C10H21 e 6.0 6.7
139 5 C12H25 e 2.2 5.1
140 5 C18H37 e 0.9 1.3
141 5 C12H25 e 1.8 1.2
a The enhancing activity of these compounds was studied in vitro, using porcine ear skin as the transdermal barrier, and theophylline as the
model drug. Water (W), isopropyl myristate (IPM) and propylene glycol/water (PG/W) was respectively used as the different donor vehicles.
Table 11 e T12 isomers with varying ester positions.a
Structure No. x y
142 2 14
143 3 13
144 4 12
145 5 11
146 6 10
147 7 9
148 9 7
149 11 5
a The enhancing activity of these compounds was studied in vitro,
using porcine ear skin as the transdermal barrier, propylene glycol/
water (PG/W) as the donor vehicle and theophylline as the model
drug.
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sitions (compound 142e149, Table 11) were studied on their
enhancing activity in a latest investigation [48]. The result
suggested that the activity of these derivatives highly depen-
ded on the positions of the ester bonds, and the optimum
performance was observed when the distance of the ester
group from the carbamate polar head reached 6e7 carbons
(compound 146e147), permitting no longer or shorter. An
intramolecular hydrogen bond between the ester carbonyl
and NeH of transkarbams might lead to the formation of a
pseudo cyclic head similar to that of Azone, which would be
one possible explanation of this result [49]. The study also
suggested that the ammonium salt (ammonium chlorides)
formed upon decomposition of the carbamate was also an
active enhancer species (compound 150e157, Table 12),
though not as effective as the corresponding Transkarbams.
Table 12 e Ammonium chloride analogs of T12.a
Structure No. x y
150 2 14
151 3 13
152 4 12
153 5 11
154 6 10
155 7 9
156 9 7
157 11 5
a The enhancing activity of these compounds was studied in vitro,
using porcine ear skin as the transdermal barrier, propylene glycol/
water (PG/W, 60/40) as the donor vehicle and theophylline as the
model drug.
Table 14 e TXA derivatives with different hydrocarbon
chain.a
Structure No. R ERa
Water IPM
Azone e 2.2 0.9
170 C8H17 1.6 2.6
171 C10H21 1.4 4.9
172 C11H23 1.3 2.9
173 C12H25 4.3 3.2
a The enhancing activity of these compounds was studied in vitro,
using human cadaver skin as the percutaneous barrier, water (W)
and isopropyl myristate (IPM) as different donor vehicles, theoph-
ylline as the model drug.
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Transkarbamswith terminalmethyl or ethyl branching in Part
III (compound 153e169, Table 13) were also prepared and
their promoting activity was evaluated by comparison with
that of their linear analogs (compound 158e162) [50]. Both of
these two kinds of transkarbams exhibited a parabolic rela-
tionship between the chain length and the permeation
enhancing activity. The best enhancement effect was
observed at around 10 carbons in the alkanol moiety in both
series, namely compound 160 and 165. No significant differ-
ence could be observed between the linear group and the
methyl-branched group with the same chain length, such as
compound 161 and 166. In the case of the ethyl-branched
analogs, the activity of compound 169 did not change signif-
icantly by comparison with its linear analog (compound 162),
however, compound 168 showed a lower activity than its
linear analog, compound 160.2.5. TXA Derivatives
Tranexamic acid (TXA) is known to improve the skin barrier
homeostasis aswell as the skin condition as awhole. Based on
the studies of T12, a series of TXA derivatives (compoundTable 13 e Transkarbams analogs with terminal methyl
or ethyl branching.a
Structure No. R ERa
158 Octyl 10.35
159 Nonyl 16.28
160 Decyl 33.60
161 Undecyl 28.86
162 Dodecyl 20.02
163 7-Methyloctyl 11.41
164 8-Methylnonyl 23.28
165 9-Methyldecyl 26.34
166 10-Methylundecyl 26.12
167 11-Methyldodecyl 18.97
168 8-Ethyldecyl 23.19
169 10-Ethyldodecyl 18.08
a The enhancing activity of these compounds was studied in vitro,
using porcine ear skin as the transdermal barrier, propylene glycol/
water (PG/W, 60/40) as the donor vehicle and theophylline as the
model drug.170e173, Table 14) were synthesized as permeation en-
hancers, which were expected to be metabolized into TXA in
viable epidermis, and hereby restore the skin barrier function
[51]. The structure of TXA is similar to 6-aminohexanoic acid,
which constitutes the polar head of T12. The only difference
between transkarbams and TXA derivatives is that TXA pos-
sesses a cyclohexane ring instead of the aliphatic chain.
TX12 (compound 173) showed an excellent activity both in
aqueous and IPM donor vehicle, which was almost two times
higher than that of Azone. However, as a result of its relative
rigidity of the cyclohexane cycle and energetically unfavor-
able change of the conformation, its activity was still lower
than T12. Degradation of the carbamate salt of TX12 was
verified in a slightly acidic environment by FTIR. Enzymolysis
of the pertinent ester bond by porcine esterase was moni-
tored by TLC and HPLC for qualitative and quantitative
investigation, proving the release of TXA in the skin. In
consequence, easier and faster recovery of the skin would be
expected as a result of a favorable influence of TXA on skin
repair process.2.6. DDAIP And DDAK
DDAIP (dodecyl 2-(dimethylamino) propanoate, compound
174, Table 15), was a potent and biodegradable enhancer that
had excellent transdermal enhancing activity towards severalTable 15 e DDAK and its derivatives.a
Structure No. n R1 R2
174 1 CH3 CH12H25
175 2 H CH12H25
176 3 H CH12H25
177 4 H CH12H25
178 5 H CH12H25
179 7 H CH12H25
180 5 H C8H17
181 5 H C9H19
182 5 H C10H21
183 5 H C11H23
a The enhancing activity of these compounds was studied in vitro,
using porcine skin as the transdermal barrier, propylene glycol/
water (PG/W, 60/40) as the donor vehicle, and theophylline as the
model drug.
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tisone and adefovir [52e55]. DDAK (compound 178, Table 15),
was synthesized by combination of the ionizable dimethyla-
mino polar head from DDAIP and 5-carbon linking group from
T12 [56,57]. The only difference between DDAK and DDAIP lies
in the linking group, in which DDAK has a longer chain length
of five carbon atoms while DDAIP has a branched linking
group. To compare these two compounds in detail, fourmodel
drugs, including theophylline, hydrocortisone, adefovir and
indomethacin were selected to evaluate the activity of the
enhancers. The results revealed that DDAK exhibited signifi-
cantly better activity than DDAIP for theophylline, hydrocor-
tisone and adefovir, while DDAIP was only better for
indomethacin. Subsequently the effect of different linking
chain length was studied with compound 175e179, which
were also shown in Table 15. An optimum linking chain length
(n ¼ 4e6) was suggested to play a significant role in the
enhancing activity of DDAK and its derivatives. By compari-
son of DDAIP and its linear isomer (compound 175, Table 15),
it was found that the branching linking group played a nega-
tive effect on the activity of DDAIP [53]. DDAK analogs with
different alky chains were also prepared (compound 178 and
180e183, Table 15) and their promoting effect on theophylline
was studied. The most potent enhancement effect was pro-
vided by compound 183. The relationship between the chain
length and the enhancement effect has a bell-like shape [58].2.7. Natural essential oils
Currently, considerable research is now in progress on the use
of natural essential oils as potential permeation enhancers to
improve the drug permeation through the skin [59]. Up to date,
many natural oils, such as niaouli oil [60], eucalyptus oil [61],
peppermint oil [62], chuanxiong oil [63], turpentine oil [64],
chlorophytum borivilianum oil [65], sweet basil oil [66] and so
on, have all been demonstrated their potential ability in
transdermal permeation enhancement for a number of hy-
drophilic and lipophilic drugs.
Natural oils from plants are mixtures of many diverse and
unique chemical compounds. Their constitutions are com-
plex and variable, depending on the growing place, season
and extraction process of the origin plants. Therefore, how to
clarify the action of natural oils remains a great challenge for
the researchers in the field of natural skin permeation en-
hancers. Gradual separation might provide a promising
method to elucidate the individual effect of each component
in the natural oils [67]. Additionally, this work would also
contribute to the formulation of certain multi-component
mixtures acting more efficiently and reproducibly with
respect to the natural essential oils [60]. Mechanistic study
revealed that natural essential oils, such as tulsi oil, euca-
lyptus oil, clove oil and black cumin oil increased the
percutaneous absorption of carvedilol by extraction of lipids
from SC as well as by loosening the hydrogen bonds between
ceramides subsequently leading to fluidization of the lipid
bilayers [61]. In addition, further research is still desirable to
scale up the natural oils for transdermal enhancement use
and implement manufacturing of final dosage forms on
commercial scale [68].3. Mechanisms of permeation enhancement
and selection of an enhancer
The mechanisms of action of permeation enhancers are
complex. According to the lipid protein partitioning (LPP)
theory proposed by Barry, enhancerswould act by one ormore
of the three main mechanisms: (a) disruption of the highly
ordered structure of the lipids in SC, (b) interaction with the
epidermal keratin and (c) improvement in partitioning of the
drug into the skin [69]. Actions on the intercellular keratin
might result in the denaturation of the protein, which was an
irreversible biological process [5]. Enhancers targeting the
keratin in SCwould also lead to great irritation to the skin [70].
Therefore, the skin irritation of a permeation enhancer would
likely be more reversible if it only interacted with the inter-
cellular lipid of the SC. In terms of lipid disruptors, they often
fall into two categories: ones that exact the lipids from the SC,
labeled “extractors,” and ones that partition into the SC lipid
bilayers exhibiting a fluidizing effect on the lipid bilayers,
labeled “fluidizers”. Generally, the lipid fluidizers regularly
outperform the lipid extractors for their little effect on the
normal constitution of the SC. Karande et al. introduced two
equations (1) and (2) to assess the safety and efficacy of the
lipid fluidizers and the lipid extractors [4]. In the equations,
the values of ER and IP respectively represent the enhance-
ment ratio and irritation potential of a CPE, and their ratio
indicates the quality to be an ideal permeation enhancer.
Obviously, for the lipid extractors, ER/IP is bound by a theo-
retical limit of one. However, no theoretical upper limit is
evident in the case of the lipid fluidizers, which indicated their
efficacy and safety as potential transdermal permeation
enhancers.
ER
IP

extractors
a
dpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d2p þ d2h þ d2d
q (1)
ER
IP

fluidizers
aLog P

dp
dh

(2)
Amphiphilicity was an important determinant for the
enhancing activity of the lipid fluidizers. In general, most of
the above mentioned permeation enhancers have the similar
structures with the SC lipids, i.e. containing a polar head and
one or two hydrophobic chains. The long chains of the
amphiphilic enhancers enable themselves to be inserted into
the intercellular lipids of the SC, and their polar heads could
interact with the polar lipid region via H-bonds and Van der
Waals force. The dual effects would effectively disturb the
orderly organization of the lipid packing, thus increasing the
diffusion of drugs with low selectivity [71]. From the analysis
of the above listed materials, there is usually an optimum
length of the hydrocarbon chain (Cn  7) that is neither
branching nor cyclization to obtain the best promoting activ-
ity. Alternatively, the changes of polar head also affect the
enhancing activity, likely bymodifying its ability of H-bonding
with the intercellular lipids.
Although LPP theory suggested a general scheme for the
mechanisms of permeation enhancement, it could not
explain the specific effectiveness of an enhancer towards one
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 5 1e6 462or a certain kind of drugs. It is likely that the precise enhancer
activity will depend on the physicochemical properties of the
enhancer as well as the penetrant, and the possible complex
formation between drugs and enhancers might be of partic-
ular importance in disruption of the transdermal barrier. For
example, Drakulic et al. has introduced a modeling method to
prove the formation of complexes between different drugs
and terpenes, and indicated their different behavior in the
process of transdermal permeation [72].
Most of the current studies have been aimed at gaining
better insights into the relationship between the structures of
the enhancers and their effectiveness in transdermal
enhancement. However, it has been confirmed that there is no
evident correlation between the permeation enhancement
effect and the skin irritation [73]. Studies of structure-
irritation relationship and mechanisms of the irritation of
the enhancer are important as well [74e76].4. Conclusion
The paper has given an overview of the investigations on the
design of novel permeation enhancers for transdermal drug
delivery systems. The list of these materials in the paper is
clearly not exhaustive, but represents the general strategies
involving in the identification of agents that can facilitate drug
delivery through the skin barrier. At the same time further
studies are also needed in the areas of skin irritation and
acting mechanisms of the skin permeation enhancers.Acknowledgment
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